PTGX Protagonist Therapeutics, Inc. | US74366E1029
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 184.566.390 | 529.831.570 | 65.17% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -0,19 | 4,47 | 104.22% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 11 | 12 | 8.33% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |